Hopkins Biologist Saul Sharkis Dies at 72; Studied Blood Stem Cells’ Role in BMT

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Saul Sharkis, a scientist who studied the biology of blood stem cells and how they could be used to treat cancer through bone marrow transplantation, died Sept. 4. He was 72.

Sharkis was a professor of oncology at the Johns Hopkins University School of Medicine and a faculty member in the Johns Hopkins Kimmel Cancer Center for more than 40 years.

A native of New York, Sharkis earned his B.A. from Hunter College and his master’s and doctoral degrees from New York University. After completing his postdoctoral research at National Naval Medical Center in Bethesda, Maryland, he was recruited to the faculty of the Johns Hopkins University School of Medicine’s Department of Oncology.

Sharkis was among the first to isolate and study hematopoietic stem cells. His research was important to the progress of bone marrow and stem cell transplants because it helped reveal the mechanisms of engraftment. His work also uncovered the biology of stem cells, isolating and tracking a stem cell population to show that small numbers of stem cells can reconstitute bone marrow following transplant.

He also studied the plasticity of blood stem cells and developed research models to explore their capacity to develop into other cells, particularly epithelial cells in the liver, pancreas, kidney, breast and intestine. These cells line the organs and are often the site where cancers begin. His hope was that one day, stem cells could be use as cellular therapy to treat cancers.

“Saul inspired us with his dedication, invaluable knowledge and experience. He was a brilliant yet humble man, a superb scientist and a Johns Hopkins innovator,” said William Nelson, director of the Johns Hopkins Kimmel Cancer. “He will be sorely missed by countless residents, fellows and colleagues.”

He is survived by brother, Alan, and sister-in-law, Anne, as well as nieces and nephews.

Table of Contents

YOU MAY BE INTERESTED IN

The University of California, San Francisco and global oncology communities mourn the death of Felix Y. Feng, MD, a radiation oncologist and a leading figure in genitourinary cancer research. A professor of radiation oncology, urology and medicine, and vice chair of translational research at the UCSF Helen Diller Family Comprehensive Cancer Center, Feng died from cancer on Dec.10, 2024. He was 48.
The late Felix Feng, MD (center) with researchers Jonathan Chou, MD, PhD (left) and Lisa Chesner, PhD (right), in 2019.Photo by Noah BergerFelix Y. Feng, a genitourinary cancer research leader, died on Dec. 10, 2024. He was 48.This article is republished with permission by NRG Oncology.Dr. Feng was the former NRG Oncology Genitourinary Cancer Committee chair and an RTOG Foundation member. After years of dedicated and enthusiastic commitment to the NRG and previously the RTOG Genitourinary Cancer Committee, chairing or co-chairing 13 research protocols for NRG and RTOG, Dr. Feng was appointed committee chair in March 2018, following in the footsteps of Dr. Howard Sandler, his mentor. Dr. Feng was also a member of the RTOG Foundation Board of Directors.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login